Overcoming Challenges Facing Advanced Therapies in the EU Market

Cell Stem Cell

Volumn 19, Issue 3, 2016, Pages 293-297

  Abou El Enein, Mohamed ^a   Elsanhoury, Ahmed ^a   Reinke, Petra ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPOGENE TIPARVOVEC; ORPHAN DRUG; SIPULEUCEL T; STRIMVELIS; TALIMOGENE LAHERPAREPVEC;

CHONDROCYTE IMPLANT; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; EUROPEAN UNION; GENE THERAPY; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; RARE DISEASE; REIMBURSEMENT; STANDARDIZATION; DRUG MANUFACTURE; ECONOMICS; HUMAN; MARKETING; PHYSICIAN; RISK FACTOR; SOCIAL CONTROL; STANDARD; TISSUE ENGINEERING;

EUROPEAN UNION; GENETIC THERAPY; HUMANS; MARKETING; ORPHAN DRUG PRODUCTION; PHYSICIANS; REFERENCE STANDARDS; RISK FACTORS; SOCIAL CONTROL, FORMAL; TISSUE ENGINEERING;

EID: 84991065600     PISSN: 19345909     EISSN: 18759777     Source Type: Journal    
DOI: 10.1016/j.stem.2016.08.012     Document Type: Note

References (10)

1. Abou-El-Enein, M., Bauer, G., Reinke, P., Renner, M., Schneider, C.K., Trends Mol. Med. 20 (2014), 632–642.
2. Abou-El-Enein, M., Bauer, G., Reinke, P., Nat. Biotechnol. 32 (2014), 1192–1193.
3. Abou-El-Enein, M., Bauer, G., Reinke, P., Trends Biotechnol. 33 (2015), 374–376.
4. Abou-El-Enein, M., Bauer, G., Medcalf, N., Volk, H.D., Reinke, P., Cytotherapy 18 (2016), 1056–1061.
5. Brindley, D.A., Reeve, B.C., Sahlman, W.A., Bonfiglio, G.A., Davie, N.L., Culme-Seymour, E.J., Mason, C., Cell Stem Cell 9 (2011), 397–401.
6. Carr, D.R., Bradshaw, S.E., Regen. Med. 11 (2016), 381–393.
7. Gammie, T., Lu, C.Y., Babar, Z.U.-D., PLOS ONE, 10, 2015, p.e0140002.
8. Ledford, H., Nature 519 (2015), 17–18.
9. Trounson, A., McDonald, C., Cell Stem Cell 17 (2015), 11–22.
10. Walker, A., Johnson, R., Biochem. Soc. Trans. 44 (2016), 329–332.